How to change the ownership from one marketing authorisation (MA) holder to another.
Similar Posts
Mesalazine and idiopathic intracranial hypertension
Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products.
Healthcare regulator suggests simple winter wellness choices to keep you safe this cough and cold season
As the cold weather sets in and coughs and colds become more common, the MHRA is reminding people that small, everyday choices can make a big difference to winter wellbeing.
Access Generic Medicines Work Sharing Initiative
This is a work sharing model for the co-ordinated assessment of a generic application that has been filed with multiple Access Consortium agencies.
MHRA Safety Roundup: May 2025
Summary of the latest safety advice for medicines and medical device users
MHRA approves imlunestrant tosylate (Inluryo) – a new treatment for breast cancer
As with any medicine, the MHRA will keep the safety and effectiveness of imlunestrant tosylate under close review.
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.